Eledon Pharmaceuticals
ELDN
83 hedge funds and large institutions have $94.5M invested in Eledon Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 22 increasing their positions, 23 reducing their positions, and 21 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
4% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 23
2% less funds holding
Funds holding: 85 → 83 (-2)
7.3% less ownership
Funds ownership: 68.21% → 60.9% (-7.3%)
15% less capital invested
Capital invested by funds: $111M → $94.5M (-$16.2M)
99% less call options, than puts
Call options by funds: $16K | Put options by funds: $1.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SL
Siren LLC
Greenwich,
Connecticut
|
+$4.04M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$3.75M |
| 3 |
CCM
Catalio Capital Management
New York
|
+$3.1M |
| 4 |
ZP
Zimmer Partners
New York
|
+$2.47M |
| 5 |
Kovitz Investment Group Partners
Chicago,
Illinois
|
+$2.14M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$7.05M |
| 2 |
AIC
AWM Investment Company
New York
|
-$2.98M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.89M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.71M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.71M |
ELDN Hedge Fund Activity: Q3 2025 in Review
83 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Eledon Pharmaceuticals (ELDN) for Q3 2025, worth a combined $94.5M — down 15% from $111M a quarter earlier.
Fund positioning in ELDN was balanced in Q3 2025: 21 funds opened new positions, 21 closed out, 22 added to existing stakes and 23 trimmed.
The largest buyer was Siren LLC, adding an estimated $4.04M. The largest seller was First Light Asset Management, exiting entirely with an estimated $7.05M sold.
- 83 institutional investors held Eledon Pharmaceuticals (ELDN) as of Q3 2025, down from 85 in Q2 2025.
- Funds reported $94.5M of Eledon Pharmaceuticals stock for Q3 2025, down 15% quarter-over-quarter.
- 21 funds opened new Eledon Pharmaceuticals positions in Q3 2025 and 21 closed out, a net change of 0 holders.
- The largest Eledon Pharmaceuticals buyer in Q3 2025 was Siren LLC, an estimated $4.04M added.
- The largest Eledon Pharmaceuticals seller in Q3 2025 was First Light Asset Management, an estimated $7.05M sold.
Based on aggregated 13F filings for Q3 2025.